OnabotulinumtoxinA Dose-Ranging Study for Hyperdynamic Perioral Lines

被引:24
|
作者
Cohen, Joel L. [1 ,2 ]
Dayan, Steven H. [3 ,4 ]
Cox, Sue Ellen [5 ,6 ]
Yalamanchili, Ramana [7 ]
Tardie, Greg [7 ]
机构
[1] AboutSkin Dermatol & DermSurg, Englewood, CO 80113 USA
[2] Univ Colorado, Dept Dermatol, Denver, CO 80202 USA
[3] Univ Illinois, Dept Otolaryngol Head & Neck Surg, Chicago, IL USA
[4] Chicago Ctr Facial Plast Surg, Chicago, IL USA
[5] Univ N Carolina, Sch Med, Dept Dermatol, Chapel Hill, NC 27514 USA
[6] Aesthet Solut, Chapel Hill, NC USA
[7] SCI Sci Commun & Informat, Parsippany, NJ USA
关键词
TOXIN TYPE-A; ACID DERMAL FILLERS; SEVERE GLABELLAR RHYTIDES; LOWER FACIAL REJUVENATION; PARALLEL-GROUP; DOUBLE-BLIND; CONSENSUS RECOMMENDATIONS; 24-MG/ML SMOOTH; FEMALE SUBJECTS; COHESIVE GEL;
D O I
10.1111/j.1524-4725.2012.02456.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Few dosing data on onabotulinumtoxinA to treat hyperdynamic perioral lines (POLs) are available. Studying onabotulinumtoxinA in controlled settings is beneficial to treating a hyperfunctional orbicularis oris. Objective To compare the dose-response relationship of two doses of onabotulinumtoxinA in hyperdynamic POLs. Methods Female subjects (N similar to=similar to 60) received injections of onabotulinumtoxinA at four sites totaling 7.5 similar to U or 12.0 similar to U. Subjects returned at weeks 2, 4, 8, 12, 16, and 20. POL severity and total lip satisfaction (TLS) were assessed at all visits. Results Investigator-assessed POL severity was reduced through week 20 for 12.0 similar to U (p similar to<similar to.01). POL reduction for 7.5 similar to U persisted until week 16 (p similar to<similar to.05). Responder rates did not differ until week 12 (12.0 similar to U, 77%; 7.5 similar to U, 36%; p similar to=similar to.003). Subject-assessed TLS was improved (p similar to<similar to.05) at all time points for both groups except at week 20 (12.0 similar to U; p similar to=similar to.06). Most adverse events (AEs) were mild to moderate in severity and typical for onabotulinumtoxinA treatment in the lips, and the incidence was dose-dependent. Conclusion OnabotulinumtoxinA provides significant reductions in POL severity and high levels of subject satisfaction. Lack of dose response and fewer AEs suggest that treatment of hyperdynamic POLs with 7.5 similar to U appears adequate for up to 16 similar to weeks.
引用
收藏
页码:1497 / 1505
页数:9
相关论文
共 50 条
  • [1] Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial
    Solish, Nowell
    Rivers, Jason K.
    Humphrey, Shannon
    Muhn, Channy
    Somogyi, Chris
    Lei, Xiaofang
    Bhogal, Meetu
    Caulkins, Carrie
    DERMATOLOGIC SURGERY, 2016, 42 (03) : 410 - 419
  • [2] STUDY DESIGNS FOR DOSE-RANGING
    SHEINER, LB
    BEAL, SL
    SAMBOL, NC
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (01) : 63 - 77
  • [3] Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Randomized Phase 2 Dose-Ranging Study
    Rohrich, Rod J.
    Bertucci, Vince
    Dayan, Steven
    Jones, Derek
    Solish, Nowell
    Rivers, Jason K.
    Weiss, Robert A.
    Muhn, Channy Y.
    Harutunian, Christy
    Park, Grace S.
    Shimoga, Sandhya
    Lee, Elisabeth
    Tong, Warren
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2025, 155 (01) : 79 - 88
  • [4] Dose-ranging studies
    Manion, D
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 1999, : 8 - 9
  • [5] IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines
    Kerscher, Martina
    Fabi, Sabrina
    Fischer, Tanja
    Gold, Michael
    Joseph, John
    Prager, Welf
    Rzany, Berthold
    Yoelin, Steve
    Roll, Susanna
    Klein, Gudrun
    Maas, Corey
    JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (10) : 1052 - 1060
  • [6] Dose-ranging study of an orlistat tablet formulation
    Schwartz, Susan M.
    Savastano, David M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (10) : 476 - 481
  • [7] INCOBOTULINUMTOXINA DEMONSTRATES SAFETY AND PROLONGED DURATION OF EFFECT IN A DOSE-RANGING STUDY FOR GLABELLAR LINES
    Kerscher, Martina
    Fabi, Sabrina
    Fischer, Tanja
    Gold, Michael
    Joseph, John
    Prager, Welf
    Rzany, Berthold
    Yoelin, Steve
    Roll, Susanna
    Klein, Gudrun
    Maas, Corey
    TOXICON, 2021, 190 : S39 - S39
  • [8] A dose-ranging study of the behavioural effects of guarana
    Haskell, CF
    Kennedy, DO
    Milne, AL
    Wesnes, KA
    Scholey, AB
    JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (05) : A45 - A45
  • [9] IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines
    Kerscher, Martina
    Fabi, Sabrina
    Fischer, Tanja
    Gold, Michael
    Joseph, John
    Prager, Welf
    Rzany, Berthold
    Yoelin, Steve
    Roll, Susanna
    Klein, Gudrun
    Maas, Corey
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (10) : 985 - 991
  • [10] A dose-ranging study of rapacuronium in pediatric patients
    Meakin, GH
    Meretoja, OA
    Motsch, J
    Taivainen, T
    Wirtavuori, K
    Schönstedt, R
    Perkins, R
    McCluskey, A
    ANESTHESIOLOGY, 2000, 92 (04) : 1002 - 1009